UY38348A - Composición para erradicar helicobacter pylori - Google Patents

Composición para erradicar helicobacter pylori

Info

Publication number
UY38348A
UY38348A UY0001038348A UY38348A UY38348A UY 38348 A UY38348 A UY 38348A UY 0001038348 A UY0001038348 A UY 0001038348A UY 38348 A UY38348 A UY 38348A UY 38348 A UY38348 A UY 38348A
Authority
UY
Uruguay
Prior art keywords
composition
helicobacter pylori
eradicate helicobacter
present
eradicate
Prior art date
Application number
UY0001038348A
Other languages
English (en)
Inventor
Bong Tae Kim
Dongkyu Kim
Eun Ji Kim
Ji Won Lee
Kyeongmin Oh
Ahrong Kim
Geun Seog Song
Shin-Young Ryu
Eun Kyung Kim
Naree Shin
Hyun Ji Kang
Jae Min Kim
Yu-Gyeong Park
Haneul Jeong
Original Assignee
Cj Healthcare Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cj Healthcare Corp filed Critical Cj Healthcare Corp
Publication of UY38348A publication Critical patent/UY38348A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición para erradicar Helicobacter pylori y su uso. La composición de la presente invención mantiene un pH intragástrico en un cierto nivel o más durante un cierto período de tiempo o más, maximizando así la acción de amoxicilina y claritromicina para mostrar un excelente efecto sobre la erradicación de Helicobacter pylori
UY0001038348A 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori UY38348A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20180102250 2018-08-29

Publications (1)

Publication Number Publication Date
UY38348A true UY38348A (es) 2020-03-31

Family

ID=69643254

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038348A UY38348A (es) 2018-08-29 2019-08-28 Composición para erradicar helicobacter pylori

Country Status (19)

Country Link
US (1) US20210196685A1 (es)
EP (1) EP3843723A4 (es)
JP (1) JP7189327B2 (es)
KR (1) KR20200026118A (es)
CN (1) CN112638378A (es)
AR (1) AR116026A1 (es)
AU (1) AU2019328903B2 (es)
BR (1) BR112021003578A2 (es)
CA (1) CA3107624C (es)
EA (1) EA202190622A1 (es)
GE (1) GEP20227431B (es)
JO (1) JOP20190201A1 (es)
MX (1) MX2021002278A (es)
MY (1) MY195494A (es)
PH (1) PH12021550385A1 (es)
SG (1) SG11202101920WA (es)
UA (1) UA126993C2 (es)
UY (1) UY38348A (es)
WO (1) WO2020045992A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190043437A (ko) 2017-10-18 2019-04-26 씨제이헬스케어 주식회사 단백질 키나제 억제제로서의 헤테로고리 화합물
WO2020210878A1 (en) * 2019-04-18 2020-10-22 Borody Thomas J Compositions and methods for treating, ameliorating and preventing h. pylori infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6753324B2 (en) * 1998-07-15 2004-06-22 Hassan Jomaa Phosphorous organic compounds and their use
WO2007072146A1 (en) * 2005-12-19 2007-06-28 Pfizer Japan Inc. Chromane substituted benzimidazoles and their use as acid pump inhibitors
CN101015694A (zh) * 2006-02-07 2007-08-15 沈阳东宇药业有限公司 一种治疗幽门螺旋杆菌感染的复方口服制剂
US10512635B2 (en) * 2015-06-08 2019-12-24 Cj Healthcare Corporation Uses of benzimidazole derivative for nocturnal acid breakthrough
US11096948B2 (en) * 2016-01-21 2021-08-24 Dexcel Pharma Technologies Ltd. Methods for treating helicobacter infection
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
CN108379258B (zh) * 2017-11-30 2020-02-18 中国医学科学院医药生物技术研究所 瑞香素在抗幽门螺杆菌中的应用

Also Published As

Publication number Publication date
GEP20227431B (en) 2022-10-25
CA3107624C (en) 2023-10-03
US20210196685A1 (en) 2021-07-01
JOP20190201A1 (ar) 2020-02-29
WO2020045992A1 (en) 2020-03-05
JP7189327B2 (ja) 2022-12-13
MX2021002278A (es) 2021-08-11
UA126993C2 (uk) 2023-03-01
CA3107624A1 (en) 2020-03-05
SG11202101920WA (en) 2021-04-29
CN112638378A (zh) 2021-04-09
AU2019328903A1 (en) 2021-04-29
EP3843723A4 (en) 2022-06-29
EP3843723A1 (en) 2021-07-07
PH12021550385A1 (en) 2021-09-20
KR20200026118A (ko) 2020-03-10
JP2021535910A (ja) 2021-12-23
BR112021003578A2 (pt) 2021-05-18
EA202190622A1 (ru) 2021-06-10
AR116026A1 (es) 2021-03-25
AU2019328903A8 (en) 2021-05-27
MY195494A (en) 2023-01-26
AU2019328903B2 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
CY1121136T1 (el) Φυτικα εκχυλισματα που περιεχουν κανναβινοειδη ως νευροπροστατευτικους παραγοντες
AR107977A1 (es) Dispositivo de suministro de vapor
GT200800276A (es) Composiciones farmaceuticas estabilizadas que comprenden fesoterodina
DK3781561T3 (da) Modulatorer af methylmodificerende enzymer, sammensætninger og anvendelser deraf
GT201200339A (es) Compuestos, composiciones de tioacetato y mètodos de uso
BR112017027147A2 (pt) agente estimulante de restauração/crescimento de cabelo
UY38348A (es) Composición para erradicar helicobacter pylori
EA202191765A1 (ru) Композиция для наружного применения, включающая жизнеспособные микроорганизмы
NI202100018A (es) Moduladores de la expresión de pnpla3
CO2021008161A2 (es) Ménsula reversible
MA52019A (fr) Schéma posologique de modulateur d'assemblage de capside
BR112018071601A2 (pt) métodos, composições e usos relacionados aos mesmos
CR11744A (es) Formulacion liquida para deferiprona con gusto agradable al paladar
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
CL2020002052A1 (es) Composiciones de edb que se dirigen a il-12.
CL2021000224A1 (es) Formulaciones y composiciones farmacéuticas que comprenden una proteína de unión a antígeno enmascarada
UY37560A (es) Combinación de un inhibidor de mcl-1 y un compuesto taxano, usos y composiciones farmacéuticas de ésta
AR100452A1 (es) Composiciones dentífricas que tienen conservantes optimizados
BR112017021611A2 (pt) ?composição para os cuidados orais, método para o branqueamento e/ou remineralização dos dentes e conjunto para os cuidados orais?
CL2021001425A1 (es) Composición acuosa estable que comprende oligosacáridos
AR109926A1 (es) Modulación de la expresión transgénica en plantas
MX2020003554A (es) Moduladores de la expresion de enac.
BR112018008065A2 (pt) composições dentifrícias com experiência do consumidor melhorada
UY38371A (es) Composición de oxima de ciclohexanodiona estabilizada